Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
Identifieur interne : 000056 ( Main/Corpus ); précédent : 000055; suivant : 000057Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
Auteurs : Enrico Scala ; Luca Fania ; Filippo Bernardini ; Rodolfo Calarco ; Sabrina Chiloiro ; Cristiana Di Campli ; Sabrina Erculei ; Mauro Giani ; Marzia Giordano ; Annarita Panebianco ; Francesca Passarelli ; Andrea Trovè ; Sofia Verkhovskaia ; Giandomenico Russo ; Antonio Sgadari ; Biagio Didona ; Damiano AbeniSource :
- Immunity, inflammation and disease [ 2050-4527 ] ; 2021.
Abstract
The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as commonly observed in other viral diseases. Considering that symptomatic patients with COVID-19 generally undergo multidrug treatments, the occurrence of a possible adverse drug reaction presenting with cutaneous manifestations should be contemplated. Pleomorphic skin eruptions occurred in a 59-year-old Caucasian woman, affected by a stable form of chronic lymphocytic leukemia, and symptomatic SARS-CoV-2 infection, treated with a combination of hydroxychloroquine sulfate, darunavir, ritonavir, sarilumb, omeprazole, ceftriaxone, high-flow oxygen therapy devices, filgrastim (Zarzio®) as a single injection, and enoxaparin. The patient stopped all treatment but oxygen and enoxaparin were continued and the patient received a high-dose Desametasone with complete remission of dermatological impairment in 10 days. It is very important to differentially diagnose COVID-19 disease-related cutaneous manifestations, where is justified to continue the multidrug antiviral treatment, from those caused by an adverse drug reaction, where it would be necessary to identify the possible culprit drug and to start appropriate antiallergic treatment.
DOI: 10.1002/iid3.382
PubMed: 33942541
Links to Exploration step
pubmed:33942541Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.</title><author><name sortKey="Scala, Enrico" sort="Scala, Enrico" uniqKey="Scala E" first="Enrico" last="Scala">Enrico Scala</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Fania, Luca" sort="Fania, Luca" uniqKey="Fania L" first="Luca" last="Fania">Luca Fania</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bernardini, Filippo" sort="Bernardini, Filippo" uniqKey="Bernardini F" first="Filippo" last="Bernardini">Filippo Bernardini</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Calarco, Rodolfo" sort="Calarco, Rodolfo" uniqKey="Calarco R" first="Rodolfo" last="Calarco">Rodolfo Calarco</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Chiloiro, Sabrina" sort="Chiloiro, Sabrina" uniqKey="Chiloiro S" first="Sabrina" last="Chiloiro">Sabrina Chiloiro</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Di Campli, Cristiana" sort="Di Campli, Cristiana" uniqKey="Di Campli C" first="Cristiana" last="Di Campli">Cristiana Di Campli</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Erculei, Sabrina" sort="Erculei, Sabrina" uniqKey="Erculei S" first="Sabrina" last="Erculei">Sabrina Erculei</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Giani, Mauro" sort="Giani, Mauro" uniqKey="Giani M" first="Mauro" last="Giani">Mauro Giani</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Giordano, Marzia" sort="Giordano, Marzia" uniqKey="Giordano M" first="Marzia" last="Giordano">Marzia Giordano</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Panebianco, Annarita" sort="Panebianco, Annarita" uniqKey="Panebianco A" first="Annarita" last="Panebianco">Annarita Panebianco</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Passarelli, Francesca" sort="Passarelli, Francesca" uniqKey="Passarelli F" first="Francesca" last="Passarelli">Francesca Passarelli</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Trove, Andrea" sort="Trove, Andrea" uniqKey="Trove A" first="Andrea" last="Trovè">Andrea Trovè</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Verkhovskaia, Sofia" sort="Verkhovskaia, Sofia" uniqKey="Verkhovskaia S" first="Sofia" last="Verkhovskaia">Sofia Verkhovskaia</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Russo, Giandomenico" sort="Russo, Giandomenico" uniqKey="Russo G" first="Giandomenico" last="Russo">Giandomenico Russo</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Sgadari, Antonio" sort="Sgadari, Antonio" uniqKey="Sgadari A" first="Antonio" last="Sgadari">Antonio Sgadari</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Didona, Biagio" sort="Didona, Biagio" uniqKey="Didona B" first="Biagio" last="Didona">Biagio Didona</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Abeni, Damiano" sort="Abeni, Damiano" uniqKey="Abeni D" first="Damiano" last="Abeni">Damiano Abeni</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33942541</idno><idno type="pmid">33942541</idno><idno type="doi">10.1002/iid3.382</idno><idno type="wicri:Area/Main/Corpus">000056</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000056</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.</title><author><name sortKey="Scala, Enrico" sort="Scala, Enrico" uniqKey="Scala E" first="Enrico" last="Scala">Enrico Scala</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Fania, Luca" sort="Fania, Luca" uniqKey="Fania L" first="Luca" last="Fania">Luca Fania</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bernardini, Filippo" sort="Bernardini, Filippo" uniqKey="Bernardini F" first="Filippo" last="Bernardini">Filippo Bernardini</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Calarco, Rodolfo" sort="Calarco, Rodolfo" uniqKey="Calarco R" first="Rodolfo" last="Calarco">Rodolfo Calarco</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Chiloiro, Sabrina" sort="Chiloiro, Sabrina" uniqKey="Chiloiro S" first="Sabrina" last="Chiloiro">Sabrina Chiloiro</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Di Campli, Cristiana" sort="Di Campli, Cristiana" uniqKey="Di Campli C" first="Cristiana" last="Di Campli">Cristiana Di Campli</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Erculei, Sabrina" sort="Erculei, Sabrina" uniqKey="Erculei S" first="Sabrina" last="Erculei">Sabrina Erculei</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Giani, Mauro" sort="Giani, Mauro" uniqKey="Giani M" first="Mauro" last="Giani">Mauro Giani</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Giordano, Marzia" sort="Giordano, Marzia" uniqKey="Giordano M" first="Marzia" last="Giordano">Marzia Giordano</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Panebianco, Annarita" sort="Panebianco, Annarita" uniqKey="Panebianco A" first="Annarita" last="Panebianco">Annarita Panebianco</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Passarelli, Francesca" sort="Passarelli, Francesca" uniqKey="Passarelli F" first="Francesca" last="Passarelli">Francesca Passarelli</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Trove, Andrea" sort="Trove, Andrea" uniqKey="Trove A" first="Andrea" last="Trovè">Andrea Trovè</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Verkhovskaia, Sofia" sort="Verkhovskaia, Sofia" uniqKey="Verkhovskaia S" first="Sofia" last="Verkhovskaia">Sofia Verkhovskaia</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Russo, Giandomenico" sort="Russo, Giandomenico" uniqKey="Russo G" first="Giandomenico" last="Russo">Giandomenico Russo</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Sgadari, Antonio" sort="Sgadari, Antonio" uniqKey="Sgadari A" first="Antonio" last="Sgadari">Antonio Sgadari</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Didona, Biagio" sort="Didona, Biagio" uniqKey="Didona B" first="Biagio" last="Didona">Biagio Didona</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Abeni, Damiano" sort="Abeni, Damiano" uniqKey="Abeni D" first="Damiano" last="Abeni">Damiano Abeni</name><affiliation><nlm:affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Immunity, inflammation and disease</title><idno type="eISSN">2050-4527</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as commonly observed in other viral diseases. Considering that symptomatic patients with COVID-19 generally undergo multidrug treatments, the occurrence of a possible adverse drug reaction presenting with cutaneous manifestations should be contemplated. Pleomorphic skin eruptions occurred in a 59-year-old Caucasian woman, affected by a stable form of chronic lymphocytic leukemia, and symptomatic SARS-CoV-2 infection, treated with a combination of hydroxychloroquine sulfate, darunavir, ritonavir, sarilumb, omeprazole, ceftriaxone, high-flow oxygen therapy devices, filgrastim (Zarzio®) as a single injection, and enoxaparin. The patient stopped all treatment but oxygen and enoxaparin were continued and the patient received a high-dose Desametasone with complete remission of dermatological impairment in 10 days. It is very important to differentially diagnose COVID-19 disease-related cutaneous manifestations, where is justified to continue the multidrug antiviral treatment, from those caused by an adverse drug reaction, where it would be necessary to identify the possible culprit drug and to start appropriate antiallergic treatment.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">33942541</PMID><DateRevised><Year>2021</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.382</ELocationID><Abstract><AbstractText>The coronavirus disease (COVID-19), during its course, may involve several organs, including the skin with a petechial skin rash, urticaria and erythematous rash, or varicella-like eruption, representing an additional effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as commonly observed in other viral diseases. Considering that symptomatic patients with COVID-19 generally undergo multidrug treatments, the occurrence of a possible adverse drug reaction presenting with cutaneous manifestations should be contemplated. Pleomorphic skin eruptions occurred in a 59-year-old Caucasian woman, affected by a stable form of chronic lymphocytic leukemia, and symptomatic SARS-CoV-2 infection, treated with a combination of hydroxychloroquine sulfate, darunavir, ritonavir, sarilumb, omeprazole, ceftriaxone, high-flow oxygen therapy devices, filgrastim (Zarzio®) as a single injection, and enoxaparin. The patient stopped all treatment but oxygen and enoxaparin were continued and the patient received a high-dose Desametasone with complete remission of dermatological impairment in 10 days. It is very important to differentially diagnose COVID-19 disease-related cutaneous manifestations, where is justified to continue the multidrug antiviral treatment, from those caused by an adverse drug reaction, where it would be necessary to identify the possible culprit drug and to start appropriate antiallergic treatment.</AbstractText><CopyrightInformation>© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scala</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-9391-9168</Identifier><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fania</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calarco</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiloiro</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Campli</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erculei</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giani</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giordano</LastName><ForeName>Marzia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panebianco</LastName><ForeName>Annarita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passarelli</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trovè</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verkhovskaia</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Giandomenico</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sgadari</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didona</LastName><ForeName>Biagio</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abeni</LastName><ForeName>Damiano</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Covid Unit, Istituto Dermopatico dell'Immacolata-IRCCS, FLMM, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Ministero della Salute: Ricerca Corrente - RC2020-2-Scala</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">cutaneous reaction</Keyword><Keyword MajorTopicYN="N">dermatology</Keyword><Keyword MajorTopicYN="N">drug reaction</Keyword><Keyword MajorTopicYN="N">skin</Keyword><Keyword MajorTopicYN="N">viral exanthem</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33942541</ArticleId><ArticleId IdType="doi">10.1002/iid3.382</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ng OT, Marimuthu K, Chia PY, et al. SARS-CoV-2 infection among travelers returning from Wuhan, China. N Engl J Med. 2020;382:1476-1478.</Citation></Reference><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.</Citation></Reference><Reference><Citation>Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-1207.</Citation></Reference><Reference><Citation>Knottnerus JA, Tugwell P. Methodological challenges in studying the COVID-19 pandemic crisis. J Clin Epidemiol. 2020;121:A5-A7.</Citation></Reference><Reference><Citation>Jewell NP, Lewnard JA, Jewell BL. Predictive mathematical models of the COVID-19 pandemic: underlying principles and value of projections. JAMA. 2020;323(19):1893-1894.</Citation></Reference><Reference><Citation>Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol. 2020;82:e177.</Citation></Reference><Reference><Citation>Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34.</Citation></Reference><Reference><Citation>Johnson RM, Vinetz JM. Dexamethasone in the management of COVID-19. BMJ. 2020;370:m2648.</Citation></Reference><Reference><Citation>Maciorowski D, Idrissi SZE, Gupta Y, et al. A review of the preclinical and clinical efficacy of remdesivir, hydroxychloroquine, and lopinavir-ritonavir treatments against COVID-19 [published online ahead of print September 17, 2020]. SLAS Discov. 2020. https://doi.org/10.1177/2472555220958385</Citation></Reference><Reference><Citation>Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost? Clin Mol Allergy. 2020;18:17.</Citation></Reference><Reference><Citation>Vinetz JM. Lack of efficacy of hydroxychloroquine in COVID-19. BMJ. 2020;369:m2018.</Citation></Reference><Reference><Citation>Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ. 2020;192:E734-E744.</Citation></Reference><Reference><Citation>Praveen D, Puvvada RC, VAM. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Int J Antimicrob Agents. 2020;55:105967.</Citation></Reference><Reference><Citation>Douedi S, Chaudhri M, Miskoff J. Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19. Ann Thorac Med. 2020;15:171-173.</Citation></Reference><Reference><Citation>Anderson DE, Tan CW, Chia WN, et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg Microbes Infect. 2020;9:900-902.</Citation></Reference><Reference><Citation>Smart L, Fawkes N, Goggin P, et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology. 2020;28:1141-1152.</Citation></Reference><Reference><Citation>Gozzo L, Viale P, Longo L, Vitale DC, Drago F. The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect: a review. Front Pharmacol. 2020;11:1307.</Citation></Reference><Reference><Citation>Paumgartten FJR, Oliveira ACAX. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Cien Saude Colet. 2020;25:3413-3419.</Citation></Reference><Reference><Citation>Scala E, Cadoni S, Girardelli CR, et al. Skewed expression of activation, differentiation and homing-related antigens in circulating cells from patients with cutaneous T cell lymphoma associated with CD7- T helper lymphocytes expansion. J Invest Dermatol. 1999;113:622-627.</Citation></Reference><Reference><Citation>Scala E, Narducci MG, Amerio P, et al. T cell receptor-Vbeta analysis identifies a dominant CD60+. J Invest Dermatol. 2002;119:193-196.</Citation></Reference><Reference><Citation>Scala E, Giani M, Pastore S, et al. Distinct delayed T-cell response to beta-methasone and penicillin-G in the same patient. Allergy. 2003;58:439-444.</Citation></Reference><Reference><Citation>Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020;83:280-285.</Citation></Reference><Reference><Citation>Ou M, Zhu J, Ji P, et al. Risk factors of severe cases with COVID-19: a meta-analysis. Epidemiol Infect. 2020;148:e175.</Citation></Reference><Reference><Citation>Scala E, Abeni D, Tedeschi A, et al. Atopic status protects from severe complications of COVID-19 [published online ahead of print August 16, 2020]. Allergy. 2020. https://doi.org/10.1111/all.14551</Citation></Reference><Reference><Citation>Weyers W, Metze D. Histopathology of drug eruptions - general criteria, common patterns, and differential diagnosis. Dermatol Pract Concept. 2011;1:33-47.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000056 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000056 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33942541
|texte= Pleomorphicskin eruptions in a COVID-19 affected patient: Case report and review of the literature.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33942541" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |